Altered cerebral γ-aminobutyric acid type a-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography

Archives of General Psychiatry

Volumn 65, Issue 10, 2008, Pages 1166-1175

  Hasler, Gregor ^a   Nugent, Allison C ^b   Carlson, Paul J ^b   Carson, Richard E ^c   Geraci, Marilla ^b   Drevets, Wayne C ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; CARBON 11; FLUMAZENIL;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG RECEPTOR BINDING; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; KINETICS; MALE; NEUROIMAGING; OUTPATIENT DEPARTMENT; PANIC; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; SUBICULUM; TEMPORAL CORTEX;

ADULT; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; CEREBRAL CORTEX; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOMINANCE, CEREBRAL; FEMALE; FLUMAZENIL; GYRUS CINGULI; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PANIC DISORDER; PARAHIPPOCAMPAL GYRUS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, GABA-A; REFERENCE VALUES; SOFTWARE;

EID: 53849102978     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.65.10.1166     Document Type: Article

References (55)

1. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415-424.
2. Hasler G, Gergen PJ, Kleinbaum DG, Ajdacic V, Gamma A, Eich D, Rossler W, Angst J. Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med. 2005;171(11):1224-1230.
3. Coryell W. Panic disorder and mortality. Psychiatr Clin North Am. 1988;11(2):433-440.
4. Charney DS, Drevets WC. Neurobiological basis of anxiety disorders. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:901-930.
5. Dorow R, Horowski R, Paschelke G, Amin M. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet. 1983;2(8341): 98-99.
6. Roy-Byrne P, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry. 1996; 153(11):1444-1449.
7. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47(10):917-925.
8. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res. 1991;36(2):115-127.
9. Brandt CA, Meller J, Keweloh L, Hoschel K, Staedt J, Munz D, Stoppe G. Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. J Neural Transm. 1998;105(10-12):1325-1333.
10. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7(suppl 1):S71-S80.
11. Kuikka JT, Pitkanen A, Lepola U, Partanen K, Vainio P, Bergstrom KA, Wieler HJ, Kaiser KP, Mittelbach L, Koponen H, et al. Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl Med Commun. 1995;16(4):273-280.
12. Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney DS. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47(2):96-106.
13. Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT: a preliminary report. Eur Arch Psychiatry Clin Neurosci. 1994;244(1): 49-51.
14. Kaschka W, Feistel H, Ebert D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res. 1995;29(5):427-434.
15. A-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55(8):715-720.
16. A-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch Gen Psychiatry. 2007;64(7):793-800.
17. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571-1575.
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2001.
19. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders: Nonpatient Edition (SCID-I/NP). New York: New York State Psychiatric Institute; 1996.
20. Maxwell ME. Manual for the Family Interview of Genetic Studies (FIGS). Bethesda, MD: National Institute of Mental Health; 1992.
21. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Arch Gen Psychiatry. 1991;48(7):603-610.
22. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22(12): 1440-1452.
23. Millet P, Graf C, Buck A, Walder B, Ibanez V. Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters. Neuroimage. 2002;17(2):928-942.
24. Poline JB, Worsley KJ, Evans AC, Friston KJ. Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage. 1997;5(2): 83-96.
25. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Georg Thieme Verlag; 1988.
26. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry. 2000;157(7):1120-1126.
27. Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. Eur J Neurosci. 1999;11(4):1470-1478.
28. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15(1):152-165.
29. Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry. 2003;60(10):993-1000.
30. 11C]flumazenil studies. J Cereb Blood Flow Metab. 2008;28(3):579-587.
31. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991;11(5):735-744.
32. 11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab. 1995;15(2):284-300.
33. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493-505.
34. Ongür D, Ferry AT, Price JL. Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comp Neurol. 2003;460(3):425-449.
35. Ongür D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex. 2000;10(3): 206-219.
36. A-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-396.
37. Weizman R, Weizman A, Kook KA, Vocci F, Deutsch SI, Paul SM. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther. 1989;249(3):701-707.
38. Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift γ-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry. 2003;60(2):161-168.
39. A receptors through two discrete transmembrane sites. Nature. 2006; 444(7118):486-489.
40. Brambilla F, Biggio G, Pisu MG, Bellodi L, Perna G, Bogdanovich-Djukic V, Purdy RH, Serra M. Neurosteroid secretion in panic disorder. Psychiatry Res. 2003; 118(2):107-116.
41. 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001; 58(6):556-561.
42. Ham BJ, Sung Y, Kim N, Kim SJ, Kim JE, Kim DJ, Lee JY, Kim JH, Yoon SJ, Lyoo IK. Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2): 403-411.
43. Schenberg LC, Bittencourt AS, Sudre EC, Vargas LC. Modeling panic attacks. Neurosci Biobehav Rev. 2001;25(7-8):647-659.
44. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci. 2000;23:155-184.
45. Bandler R, Keay KA, Floyd N, Price J. Central circuits mediating patterned autonomic activity during active vs passive emotional coping. Brain Res Bull. 2000; 53(1):95-104.
46. Drevets WC, Raichle ME. Reciprocal suppression of regional cerebral blood flow during emotional versus higher cognitive processes: implications for interactions between emotion and cognition. Cogn Emotion. 1998;12:353-385.
47. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry. 2002;52(2):126-135.
48. Quirk GJ, Garcia R, Gonzalez-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry. 2006;60(4):337-343.
49. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature. 2002;420(6911):70-74.
50. Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature. 1984;310(5979): 683-685.
51. De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry. 1993;33(7):505-512.
52. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, Gasto C, Junque C, Massana J, Mercader JM. Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. Am J Psychiatry. 2003;160(3):566-568.
53. Gray JA. The Neuropsychology of Anxiety: An Enquiry Into the Functions of the Septo-Hippocampal System. Oxford, England: Oxford University Press; 1982.
54. Garcia R, Vouimba RM, Baudry M, Thompson RF. The amygdala modulates pre-frontal cortex activity relative to conditioned fear. Nature. 1999;402(6759): 294-296.
55. Morgan MA, LeDoux JE. Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Behav Neurosci. 1995;109(4):681-688.